第一单位：
Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
作者：
João M,Fernandes Neto [1]
;
Ernest,Nadal [2]
;
Evert,Bosdriesz [3]
;
Salo N,Ooft [4]
;
Lourdes,Farre [5]
;
Chelsea,McLean [4]
;
Sjoerd,Klarenbeek [6]
;
Anouk,Jurgens [1]
;
Hannes,Hagen [1]
;
Liqin,Wang [1]
;
Enriqueta,Felip [7]
;
Alex,Martinez-Marti [7]
;
August,Vidal [2]
;
Emile,Voest [4]
;
Lodewyk F A,Wessels [1]
;
Olaf,van Tellingen [8]
;
Alberto,Villanueva [9]
;
René,Bernards [10]
作者单位：
Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
[1]
Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.
[2]
Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.;Department of Computer Science, Faculty of Science, Vrije Universiteit, Amsterdam, The Netherlands.
[3]
Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands.
[4]
Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.;Institute Gonçalo Moniz, Fundaçao Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brasil.
[5]
Experimental Animal Pathology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands.
[6]
Department of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.;Autonomous University of Barcelona (UAB), Barcelona, Spain.
[7]
Division of Clinical Pharmacology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands.
[8]
Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.;Xenopat S.L., Business Bioincubator, Bellvitge Health Science Campus, Barcelona, Spain.
[9]
Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. r.bernards@nki.nl.
[10]
主题词
动物(Animals);抗肿瘤药(Antineoplastic Agents);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);细胞系, 肿瘤(Cell Line, Tumor);细胞增殖(Cell Proliferation);抗药性, 肿瘤(Drug Resistance, Neoplasm);人类(Humans);肺肿瘤(Lung Neoplasms);MAP激酶信号系统(MAP Kinase Signaling System);小鼠(Mice);模型, 动物(Models, Animal);突变(Mutation);蛋白激酶抑制剂(Protein Kinase Inhibitors);肿瘤细胞, 培养的(Tumor Cells, Cultured)
DOI
10.1038/s41467-020-16952-9
PMID
32572029
发布时间
2021-06-22
换一批
